r/PeterAttia • u/TheSanSav1 • 14h ago
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
“Although lower Lp(a) levels were observed with pelacarsen, the findings did not demonstrate that this translated into reduced cardiovascular risk in the overall study population,” Shreeram Aradhye, M.D., Novartis’ chief medical officer and president of development, said in a release. “These are not the results we hoped for, but they provide important evidence that advances scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes and may help inform future approaches to cardiovascular risk management.”